Low dose Naltrexone is an oral treatment with very few side effects; however its availability to MS patients is limited by the lack of available research evidence to show its safety and efficacy. LDN is a non patentable drug which will be unlikely to generate profits for any company which may be interested in researching it. Here we propose to test the efficacy of LDN in terms of quality of life assessments over a six month period in a double blind placebo controlled randomised trial in forty MS

The objectives are to determine the efficacy and safety of low dose Naltrexone in patients with either primary or secondary progressive multiple sclerosis. If the results from this study are positive it is hoped that it could be instrumental in increasing access to the drug worldwide.